Enantioselective Rocaglamide Synthesis via Oxidopyrylium Photocycloaddition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic approaches lack a unified method for the production of rocaglamide, aglain, and forbaglin natural products, which are known for their potent anticancer and NF-κB inhibitory activities, with existing methods being inefficient and non-enantioselective.
Innovation Solution
A method involving photochemical generation of an oxidopyrylium species through excited state intramolecular proton transfer, followed by enantioselective [3+2] cycloaddition with a dipolarophile in the presence of a functionalized TADDOL derivative, allowing for the synthesis of chiral, nonracemic rocaglate derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional synthetic approaches are used for rocaglamide production, then multiple separate methods are required for different natural products, but this results in lack of unity and inefficiency in synthesis
Solution Approach 1:
The patent applies universality by developing a single photochemical [3+2] cycloaddition methodology that can synthesize multiple different natural products (rocaglamides, aglains, and forbaglins) through variation of starting materials. This unified approach replaces multiple separate synthetic routes with one versatile method, directly resolving the contradiction between adaptability and productivity.
2Manufacturing precision
If conventional synthesis methods are used, then racemic mixtures are produced, but this results in loss of enantioselectivity and biological activity
Solution Approach 1:
The patent employs chiral Brønsted acid catalysts as intermediaries to mediate the photochemical cycloaddition reaction. These catalysts transfer chiral information to the transition state, enabling enantioselective formation of the cyclopenta[b]tetrahydrobenzofuran core. The intermediary catalyst resolves the contradiction by providing enantioselectivity without requiring complex chiral pool starting materials.
Solution Approach 2:
The patent achieves enantioselectivity by changing the chemical parameter of the reaction system - introducing chiral Brønsted acid catalysts that modify the reaction pathway. This parameter change transforms the achiral photochemical process into an enantioselective transformation, resolving the contradiction between manufacturing precision and device complexity.
3Manufacturing precision
If traditional photocycloaddition methods are used, then the reaction lacks enantioselectivity, but adding chiral catalysts increases process complexity
Solution Approach 1:
The patent resolves this contradiction by changing the chemical parameter of introducing chiral Brønsted acid catalysts with specific structural features (such as TADDOL derivatives). These catalysts provide enantioselectivity through their chiral environment while maintaining relatively simple reaction conditions, thus achieving high enantiomeric excess without excessive process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the efficient and enantioselective synthesis of rocaglamide derivatives, providing a scalable route to these biologically active compounds with potential applications in cancer treatment and NF-κB-associated conditions.
Implementation Method 1
photochemical generation of an oxidopyrylium species through excited state intramolecular proton transfer
Implementation Method 2
excited state intramolecular proton transfer
Implementation Method 3
enantioselective [3+2] cycloaddition with a dipolarophile
Data Source
AI summary
The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-κB-dependent conditions.